Build Your Comparison

Side-by-side financial analysis
NYXH logo
NYXH
AVAV logo
AVAV
KTOS logo
KTOS
INSP logo
INSP
JPM logo
JPM
Try popular comparisons:

Stock Comparison

NYXH vs AVAV vs KTOS vs INSP vs JPM

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
NYXH
Nyxoah S.A.

Medical - Instruments & Supplies

HealthcareNASDAQ • BE
Market Cap$52M
5Y Perf.-94.2%
AVAV
AeroVironment, Inc.

Aerospace & Defense

IndustrialsNASDAQ • US
Market Cap$8.52B
5Y Perf.+54.6%
KTOS
Kratos Defense & Security Solutions, Inc.

Aerospace & Defense

IndustrialsNASDAQ • US
Market Cap$10.83B
5Y Perf.+116.0%
INSP
Inspire Medical Systems, Inc.

Medical - Devices

HealthcareNYSE • US
Market Cap$1.23B
5Y Perf.-82.0%
JPM
JPMorgan Chase & Co.

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$896.00B
5Y Perf.+108.5%

NYXH vs AVAV vs KTOS vs INSP vs JPM — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
NYXH logoNYXH
AVAV logoAVAV
KTOS logoKTOS
INSP logoINSP
JPM logoJPM
IndustryMedical - Instruments & SuppliesAerospace & DefenseAerospace & DefenseMedical - DevicesBanks - Diversified
Market Cap$52M$8.52B$10.83B$1.23B$896.00B
Revenue (TTM)$16M$1.61B$1.42B$915M$280.33B
Net Income (TTM)$-86M$-224M$29M$131M$57.05B
Gross Margin48.3%21.8%18.3%85.8%60.0%
Operating Margin-5.3%-8.3%1.8%5.6%25.9%
Forward P/E59.2x75.9x47.6x14.4x
Total Debt$42M$64M$180M$32M$942.38B
Cash & Equiv.$30M$41M$561M$105M$343.34B

NYXH vs AVAV vs KTOS vs INSP vs JPMLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

NYXH
AVAV
KTOS
INSP
JPM
StockApr 21Jun 26Return
Nyxoah S.A. (NYXH)1005.8-94.2%
AeroVironment, Inc. (AVAV)100154.6+54.6%
Kratos Defense & Se… (KTOS)100216.0+116.0%
Inspire Medical Sys… (INSP)10018.0-82.0%
JPMorgan Chase & Co. (JPM)100208.5+108.5%

Price return only. Dividends and distributions are not included.

Quick Verdict: NYXH vs AVAV vs KTOS vs INSP vs JPM

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: JPM leads in 4 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Nyxoah S.A. is the stronger pick specifically for growth and revenue expansion. KTOS and INSP also each lead in at least one category. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
🥇JPM emerged as the overall leader. Track its performance:
NYXH
Nyxoah S.A.
The Growth Play

NYXH is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 121.6%, EPS growth -30.9%, 3Y rev CAGR 48.1%
  • 121.6% revenue growth vs JPM's 3.3%
Best for: growth exposure
AVAV
AeroVironment, Inc.
The Industrials Pick

Among these 5 stocks, AVAV doesn't own a clear edge in any measured category.

Best for: industrials exposure
KTOS
Kratos Defense & Security Solutions, Inc.
The Long-Run Compounder

KTOS ranks third and is worth considering specifically for long-term compounding.

  • 13.5% 10Y total return vs JPM's 465.8%
  • +40.0% vs NYXH's -81.6%
Best for: long-term compounding
INSP
Inspire Medical Systems, Inc.
The Defensive Pick

INSP is the clearest fit if your priority is sleep-well-at-night and defensive.

  • Lower volatility, beta 1.16, Low D/E 4.1%, current ratio 6.08x
  • Beta 1.16, current ratio 6.08x
  • 15.2% ROA vs NYXH's -80.8%, ROIC 6.0% vs -76.4%
Best for: sleep-well-at-night and defensive
JPM
JPMorgan Chase & Co.
The Banking Pick

JPM carries the broadest edge in this set and is the clearest fit for income & stability.

  • Dividend streak 15 yrs, beta 0.94, yield 1.9%
  • Lower P/E (14.4x vs 47.6x)
  • 20.4% margin vs NYXH's -5.3%
  • Beta 0.94 vs KTOS's 2.18
Best for: income & stability
See the full category breakdown
CategoryWinnerWhy
GrowthNYXH logoNYXH121.6% revenue growth vs JPM's 3.3%
ValueJPM logoJPMLower P/E (14.4x vs 47.6x)
Quality / MarginsJPM logoJPM20.4% margin vs NYXH's -5.3%
Stability / SafetyJPM logoJPMBeta 0.94 vs KTOS's 2.18
DividendsJPM logoJPM1.9% yield; 15-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)KTOS logoKTOS+40.0% vs NYXH's -81.6%
Efficiency (ROA)INSP logoINSP15.2% ROA vs NYXH's -80.8%, ROIC 6.0% vs -76.4%

NYXH vs AVAV vs KTOS vs INSP vs JPM — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Defense Stocks Theme

These companies are key players in the Defense Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
NYXHNyxoah S.A.

Segment breakdown not available.

AVAVAeroVironment, Inc.
FY 2024
Product sales
81.7%$586M
Contract services
18.3%$131M
KTOSKratos Defense & Security Solutions, Inc.
FY 2025
Product
65.2%$878M
Service
34.8%$469M
INSPInspire Medical Systems, Inc.
FY 2025
Operating Segment
100.0%$912M
JPMJPMorgan Chase & Co.
FY 2025
Commercial And Investment Bank
43.0%$78.5B
Consumer & Community Banking
41.7%$76.0B
Asset and Wealth Management Segment
13.2%$24.1B
Segment Reporting, Reconciling Item, Corporate Nonsegment
3.9%$7.0B
Segment Reconciling Items
-1.7%$-3,134,000,000

NYXH vs AVAV vs KTOS vs INSP vs JPM — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLJPMLAGGINGAVAV

Income & Cash Flow (Last 12 Months)

JPM leads this category, winning 3 of 6 comparable metrics.

JPM is the larger business by revenue, generating $280.3B annually — 17179.4x NYXH's $16M. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to NYXH's -5.3%. On growth, NYXH holds the edge at +5.9% YoY revenue growth, suggesting stronger near-term business momentum.

MetricNYXH logoNYXHNyxoah S.A.AVAV logoAVAVAeroVironment, In…KTOS logoKTOSKratos Defense & …INSP logoINSPInspire Medical S…JPM logoJPMJPMorgan Chase & …
RevenueTrailing 12 months$16M$1.6B$1.4B$915M$280.3B
EBITDAEarnings before interest/tax-$81M$82M$72M$62M$81.4B
Net IncomeAfter-tax profit-$86M-$224M$29M$131M$57.0B
Free Cash FlowCash after capex-$73M-$183M-$134M$97M$100.9B
Gross MarginGross profit ÷ Revenue+48.3%+21.8%+18.3%+85.8%+60.0%
Operating MarginEBIT ÷ Revenue-5.3%-8.3%+1.8%+5.6%+25.9%
Net MarginNet income ÷ Revenue-5.3%-13.9%+2.1%+14.3%+20.4%
FCF MarginFCF ÷ Revenue-4.5%-11.3%-9.5%+10.6%+36.0%
Rev. Growth (YoY)Latest quarter vs prior year+5.9%+143.4%+22.6%+1.6%
EPS Growth (YoY)Latest quarter vs prior year+38.3%-51.5%+133.3%-5.0%+16.0%
JPM leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

Evenly matched — NYXH and INSP and JPM each lead in 2 of 6 comparable metrics.

At 8.7x trailing earnings, INSP trades at a 98% valuation discount to KTOS's 444.2x P/E. On an enterprise value basis, INSP's 17.8x EV/EBITDA is more attractive than KTOS's 120.1x.

MetricNYXH logoNYXHNyxoah S.A.AVAV logoAVAVAeroVironment, In…KTOS logoKTOSKratos Defense & …INSP logoINSPInspire Medical S…JPM logoJPMJPMorgan Chase & …
Market CapShares × price$52M$8.5B$10.8B$1.2B$896.0B
Enterprise ValueMkt cap + debt − cash$66M$8.5B$10.4B$1.2B$1.50T
Trailing P/EPrice ÷ TTM EPS-0.51x110.05x444.23x8.73x16.00x
Forward P/EPrice ÷ next-FY EPS est.59.24x75.89x47.59x14.40x
PEG RatioP/E ÷ EPS growth rate0.90x
EV / EBITDAEnterprise value multiple104.43x120.10x17.83x18.36x
Price / SalesMarket cap ÷ Revenue4.48x10.38x8.04x1.35x3.20x
Price / BookPrice ÷ Book value/share0.93x5.42x5.01x1.63x2.47x
Price / FCFMarket cap ÷ FCF15.68x8.88x
Evenly matched — NYXH and INSP and JPM each lead in 2 of 6 comparable metrics.

Profitability & Efficiency

INSP leads this category, winning 7 of 9 comparable metrics.

INSP delivers a 18.0% return on equity — every $100 of shareholder capital generates $18 in annual profit, vs $-164 for NYXH. INSP carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), INSP scores 7/9 vs NYXH's 2/9, reflecting strong financial health.

MetricNYXH logoNYXHNyxoah S.A.AVAV logoAVAVAeroVironment, In…KTOS logoKTOSKratos Defense & …INSP logoINSPInspire Medical S…JPM logoJPMJPMorgan Chase & …
ROE (TTM)Return on equity-164.4%-6.4%+1.3%+18.0%+15.9%
ROA (TTM)Return on assets-80.8%-5.0%+1.0%+15.2%+1.3%
ROICReturn on invested capital-76.4%+3.6%+1.4%+6.0%+4.5%
ROCEReturn on capital employed-80.4%+4.5%+1.5%+6.7%+8.9%
Piotroski ScoreFundamental quality 0–923475
Debt / EquityFinancial leverage0.86x0.07x0.09x0.04x2.60x
Net DebtTotal debt minus cash$12M$23M-$381M-$73M$599.0B
Cash & Equiv.Liquid assets$30M$41M$561M$105M$343.3B
Total DebtShort + long-term debt$42M$64M$180M$32M$942.4B
Interest CoverageEBIT ÷ Interest expense-32.73x-5.99x6.16x418.58x0.74x
INSP leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

KTOS leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in KTOS five years ago would be worth $21,950 today (with dividends reinvested), compared to $515 for NYXH. Over the past 12 months, KTOS leads with a +40.0% total return vs NYXH's -81.6%. The 3-year compound annual growth rate (CAGR) favors KTOS at 59.1% vs INSP's -48.0% — a key indicator of consistent wealth creation.

MetricNYXH logoNYXHNyxoah S.A.AVAV logoAVAVAeroVironment, In…KTOS logoKTOSKratos Defense & …INSP logoINSPInspire Medical S…JPM logoJPMJPMorgan Chase & …
YTD ReturnYear-to-date-69.1%-33.4%-27.2%-53.7%-0.5%
1-Year ReturnPast 12 months-81.6%-10.3%+40.0%-66.8%+21.8%
3-Year ReturnCumulative with dividends-82.4%+76.1%+302.4%-85.9%+138.2%
5-Year ReturnCumulative with dividends-94.9%+50.6%+119.5%-77.3%+118.2%
10-Year ReturnCumulative with dividends-94.2%+445.9%+1354.7%+70.9%+465.8%
CAGR (3Y)Annualised 3-year return-44.0%+20.8%+59.1%-48.0%+33.6%
KTOS leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

JPM leads this category, winning 2 of 2 comparable metrics.

JPM is the less volatile stock with a 0.94 beta — it tends to amplify market swings less than KTOS's 2.18 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 95.1% from its 52-week high vs NYXH's 16.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricNYXH logoNYXHNyxoah S.A.AVAV logoAVAVAeroVironment, In…KTOS logoKTOSKratos Defense & …INSP logoINSPInspire Medical S…JPM logoJPMJPMorgan Chase & …
Beta (5Y)Sensitivity to S&P 5002.10x1.90x2.18x1.16x0.94x
52-Week HighHighest price in past year$8.59$417.86$134.00$147.03$337.25
52-Week LowLowest price in past year$1.26$156.29$39.00$38.91$262.71
% of 52W HighCurrent price vs 52-week peak+16.2%+40.8%+43.1%+29.0%+95.1%
RSI (14)Momentum oscillator 0–10025.849.448.343.359.1
Avg Volume (50D)Average daily shares traded189K1.1M4.2M950K7.0M
JPM leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

JPM leads this category, winning 1 of 1 comparable metric.

Analyst consensus: NYXH as "Buy", AVAV as "Buy", KTOS as "Buy", INSP as "Hold", JPM as "Buy". Consensus price targets imply 331.7% upside for NYXH (target: $6) vs 5.9% for JPM (target: $340). JPM is the only dividend payer here at 1.86% yield — a key consideration for income-focused portfolios.

MetricNYXH logoNYXHNyxoah S.A.AVAV logoAVAVAeroVironment, In…KTOS logoKTOSKratos Defense & …INSP logoINSPInspire Medical S…JPM logoJPMJPMorgan Chase & …
Analyst RatingConsensus buy/hold/sellBuyBuyBuyHoldBuy
Price TargetConsensus 12-month target$6.00$292.20$110.00$57.36$339.75
# AnalystsCovering analysts528242761
Dividend YieldAnnual dividend ÷ price+1.9%
Dividend StreakConsecutive years of raises015
Dividend / ShareAnnual DPS$5.95
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%+14.2%+3.9%
JPM leads this category, winning 1 of 1 comparable metric.
Key Takeaway

JPM leads in 3 of 6 categories (Income & Cash Flow, Risk & Volatility). INSP leads in 1 (Profitability & Efficiency). 1 tied.

Best OverallJPMorgan Chase & Co. (JPM)Leads 3 of 6 categories
Loading custom metrics...

NYXH vs AVAV vs KTOS vs INSP vs JPM: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is NYXH or AVAV or KTOS or INSP or JPM a better buy right now?

For growth investors, Nyxoah S.

A. (NYXH) is the stronger pick with 121. 6% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). Inspire Medical Systems, Inc. (INSP) offers the better valuation at 8. 7x trailing P/E (47. 6x forward), making it the more compelling value choice. Analysts rate Nyxoah S. A. (NYXH) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — NYXH or AVAV or KTOS or INSP or JPM?

On trailing P/E, Inspire Medical Systems, Inc.

(INSP) is the cheapest at 8. 7x versus Kratos Defense & Security Solutions, Inc. at 444. 2x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 4x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — NYXH or AVAV or KTOS or INSP or JPM?

Over the past 5 years, Kratos Defense & Security Solutions, Inc.

(KTOS) delivered a total return of +119. 5%, compared to -94. 9% for Nyxoah S. A. (NYXH). Over 10 years, the gap is even starker: KTOS returned +1355% versus NYXH's -94. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — NYXH or AVAV or KTOS or INSP or JPM?

By beta (market sensitivity over 5 years), JPMorgan Chase & Co.

(JPM) is the lower-risk stock at 0. 94β versus Kratos Defense & Security Solutions, Inc. 's 2. 18β — meaning KTOS is approximately 132% more volatile than JPM relative to the S&P 500. On balance sheet safety, Inspire Medical Systems, Inc. (INSP) carries a lower debt/equity ratio of 4% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

05

Which is growing faster — NYXH or AVAV or KTOS or INSP or JPM?

By revenue growth (latest reported year), Nyxoah S.

A. (NYXH) is pulling ahead at 121. 6% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: Inspire Medical Systems, Inc. grew EPS 179. 4% year-over-year, compared to -30. 9% for Nyxoah S. A.. Over a 3-year CAGR, NYXH leads at 48. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — NYXH or AVAV or KTOS or INSP or JPM?

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -899. 1% for Nyxoah S. A. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -827. 8% for NYXH. At the gross margin level — before operating expenses — INSP leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is NYXH or AVAV or KTOS or INSP or JPM more undervalued right now?

On forward earnings alone, JPMorgan Chase & Co.

(JPM) trades at 14. 4x forward P/E versus 75. 9x for Kratos Defense & Security Solutions, Inc. — 61. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NYXH: 331. 7% to $6. 00.

08

Which pays a better dividend — NYXH or AVAV or KTOS or INSP or JPM?

In this comparison, JPM (1.

9% yield) pays a dividend. NYXH, AVAV, KTOS, INSP do not pay a meaningful dividend and should not be held primarily for income.

09

Is NYXH or AVAV or KTOS or INSP or JPM better for a retirement portfolio?

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Nyxoah S. A. (NYXH) carries a higher beta of 2. 10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, NYXH: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between NYXH and AVAV and KTOS and INSP and JPM?

These companies operate in different sectors (NYXH (Healthcare) and AVAV (Industrials) and KTOS (Industrials) and INSP (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NYXH is a small-cap high-growth stock; AVAV is a small-cap quality compounder stock; KTOS is a mid-cap high-growth stock; INSP is a small-cap deep-value stock; JPM is a large-cap deep-value stock. JPM pays a dividend while NYXH, AVAV, KTOS, INSP do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.